Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Rating of “Buy” from Analysts

Krystal Biotech, Inc. (NASDAQ:KRYS) has been given an average rating of “Buy” by the eight brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $220.00.

KRYS has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price objective on the stock. Citigroup raised their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th. Chardan Capital increased their price target on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday, February 20th. Finally, HC Wainwright restated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th.

Krystal Biotech Trading Up 1.1 %

Shares of NASDAQ:KRYS opened at $179.38 on Monday. The stock has a fifty day simple moving average of $163.50 and a two-hundred day simple moving average of $173.69. Krystal Biotech has a 12-month low of $141.72 and a 12-month high of $219.34. The stock has a market capitalization of $5.17 billion, a price-to-earnings ratio of 59.99 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. During the same period in the previous year, the company earned $0.30 earnings per share. The business’s revenue for the quarter was up 116.4% compared to the same quarter last year. As a group, equities research analysts predict that Krystal Biotech will post 6.14 EPS for the current year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors have recently added to or reduced their stakes in KRYS. US Bancorp DE grew its stake in Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company’s stock valued at $161,000 after acquiring an additional 82 shares in the last quarter. Summit Investment Advisors Inc. grew its position in shares of Krystal Biotech by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company’s stock valued at $407,000 after purchasing an additional 82 shares in the last quarter. Crossmark Global Holdings Inc. grew its position in shares of Krystal Biotech by 5.5% during the fourth quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock valued at $362,000 after purchasing an additional 121 shares in the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Krystal Biotech by 1.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company’s stock worth $1,822,000 after purchasing an additional 121 shares during the last quarter. Finally, Perigon Wealth Management LLC lifted its position in shares of Krystal Biotech by 1.5% in the fourth quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company’s stock worth $1,200,000 after buying an additional 123 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).